Multi-4SCAR-T Therapy Targeting Breast Cancer

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT04430595
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • 4SCAR T cells — BIOLOGICAL
    Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells

Study Details

The purpose of this study is to assess the feasibility, safety and efficacy of multiple 4th generation CAR-T cells targeting Her2, GD2, and CD44v6 surface antigen in breast cancer. Another goal of the study is to learn more about the activities of the multi-CAR T cells and their persistency in the patients.

Key Dates

First listed
Jun 12, 2020
Start date
Jun 1, 2027
Status verified
Aug 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Multiple 4SCAR T cells to treat breast cancer
    Multiple 4SCAR T cells to treat breast cancer

Primary Outcome Measure

Number of patients with adverse events. [ Time Frame: 3 year ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsOncology trialsBreast oncology trialsWomen's health trials

Related Studies